Flavonoids represent a potential source of new antitrypanosomatidic leads. Starting from a library of natural products, we combined target-based screening on pteridine reductase 1 with phenotypic screening on Trypanosoma brucei for hit identification. Flavonols were identified as hits, and a library of 16 derivatives was synthesized. Twelve compounds showed EC50 values against T. brucei below 10 μM. Four X-ray crystal structures and docking studies explained the observed structure-activity relationships. Compound 2 (3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one) was selected for pharmacokinetic studies. Encapsulation of compound 2 in PLGA nanoparticles or cyclodextrins resulted in lower in vitro toxicity when compared to the free compound. Combination studies with methotrexate revealed that compound 13 (3-hydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one) has the highest synergistic effect at concentration of 1.3 μM, 11.7-fold dose reduction index and no toxicity toward host cells. Our results provide the basis for further chemical modifications aimed at identifying novel antitrypanosomatidic agents showing higher potency toward PTR1 and increased metabolic stability.
Pteridine reductase-1 (PTR1) is a promising
drug target for the treatment of trypanosomiasis. We investigated
the potential of a previously identified class of thiadiazole inhibitors
of Leishmania major PTR1 for activity
against Trypanosoma brucei (Tb). We solved crystal structures of several TbPTR1-inhibitor complexes to guide the structure-based design of new
thiadiazole derivatives. Subsequent synthesis and enzyme- and cell-based
assays confirm new, mid-micromolar inhibitors of TbPTR1 with low toxicity. In particular, compound 4m,
a biphenyl-thiadiazole-2,5-diamine with IC50 = 16 μM,
was able to potentiate the antitrypanosomal activity of the dihydrofolate
reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of
the EC50 value. In addition, the antiparasitic activity
of the combination of 4m and MTX was reversed by addition
of folic acid. By adopting an efficient hit discovery platform, we
demonstrate, using the 2-amino-1,3,4-thiadiazole scaffold, how a promising
tool for the development of anti-T. brucei agents can be obtained.
The pharmacodynamics of drug-candidates is often optimized by metrics that describe target binding (Kd or Ki value) or target modulation (IC50). However, these metrics are determined at equilibrium conditions, and consequently information regarding the onset and offset of target engagement and modulation is lost. Drug-target residence time is a measure for the lifetime of the drug-target complex, which has recently been receiving considerable interest, as target residence time is shown to have prognostic value for the in vivo efficacy of several drugs. In this study, we have investigated the relation between the increased residence time of antihistamines at the histamine H1 receptor (H1R) and the duration of effective target-inhibition by these antagonists. Hela cells, endogenously expressing low levels of the H1R, were incubated with a series of antihistamines and dissociation was initiated by washing away the unbound antihistamines. Using a calcium-sensitive fluorescent dye and a label free, dynamic mass redistribution based assay, functional recovery of the H1R responsiveness was measured by stimulating the cells with histamine over time, and the recovery was quantified as the receptor recovery time. Using these assays, we determined that the receptor recovery time for a set of antihistamines differed more than 40-fold and was highly correlated to their H1R residence times, as determined with competitive radioligand binding experiments to the H1R in a cell homogenate. Thus, the receptor recovery time is proposed as a cell-based and physiologically relevant metric for the lead optimization of G protein-coupled receptor antagonists, like the H1R antagonists. Both, label-free or real-time, classical signaling assays allow an efficient and physiologically relevant determination of kinetic properties of drug molecules.
18Increased Gram-negative bacteria resistance to antibiotics is becoming a global problem and new 19 classes of antibiotics with novel mechanisms of action are required. The caseinolytic protease subunit 20 P (ClpP) is a serine protease conserved among bacteria that is considered as an interesting drug target. 21ClpP function is involved in protein turnover and homeostasis, stress-response and virulence among 22 other processes. The focus of this study was to identify new inhibitors of Escherichia coli ClpP and to 23 understand their mode of action. A focused library of serine protease inhibitors based on diaryl 24 phosphonate warheads was tested for ClpP inhibition and a chemical exploration around the hit 25 compounds was conducted. Altogether 14 new potent inhibitors of E. coli ClpP were identified. 26
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.